{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:12:00Z","timestamp":1762459920881,"version":"3.41.2"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.01632","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T04:29:17Z","timestamp":1599107357000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Correlation Patterns Among B7 Family Ligands and Tryptophan Degrading Enzymes in Hepatocellular Carcinoma"],"prefix":"10.3389","volume":"10","author":[{"given":"Raghavan","family":"Chinnadurai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafaela","family":"Scandolara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olatunji B.","family":"Alese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalia","family":"Arafat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Ravindranathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alton B.","family":"Farris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bassel F.","family":"El-Rayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","article-title":"Hepatocellular carcinoma","volume":"2","author":"Llovet","year":"2016","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000481245","article-title":"Immuno-oncology in hepatocellular carcinoma: 2017 update","volume":"93","author":"Kudo","year":"2017","journal-title":"Oncology."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"B5","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3389\/fonc.2018.00423","article-title":"Updates in the clinical development of epacadostat and other indoleamine 2,3-dioxygenase 1 inhibitors (IDO1) for human cancers","volume":"8","author":"Komiya","year":"2018","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.3389\/fimmu.2019.01801","article-title":"Limitations and off-target effects of tryptophan-related IDO inhibitors in cancer treatment","volume":"10","author":"Gunther","year":"2019","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1158\/1078-0432.CCR-18-2882","article-title":"Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan-kynurenine-aryl hydrocarbon axis","volume":"25","author":"Labadie","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e957994","DOI":"10.4161\/21624011.2014.957994","article-title":"Trial watch: IDO inhibitors in cancer therapy","volume":"3","author":"Vacchelli","year":"2014","journal-title":"Oncoimmunology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1002\/cncr.32076","article-title":"Immune checkpoint inhibitors for hepatocellular carcinoma","volume":"125","author":"El Dika","year":"2019","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s40425-019-0749-z","article-title":"Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response","volume":"7","author":"Keenan","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.immuni.2016.05.002","article-title":"Coinhibitory pathways in the B7-CD28 ligand-receptor family","volume":"44","author":"Schildberg","year":"2016","journal-title":"Immunity"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1158\/1535-7163.MCT-16-0761","article-title":"New B7 family checkpoints in human cancers","volume":"16","author":"Ni","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1172\/JCI120775","article-title":"Emerging strategies for combination checkpoint modulators in cancer immunotherapy","volume":"128","author":"Popovic","year":"2018","journal-title":"J Clin Invest"},{"key":"B17","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining 'T cell exhaustion'","volume":"19","author":"Blank","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00281-019-00744-5","article-title":"CD8(+) T cell exhaustion","volume":"41","author":"Kurachi","year":"2019","journal-title":"Semin Immunopathol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/ni947","article-title":"Costimulation through the inducible costimulator ligand is essential for both T helper and B cell functions in T cell-dependent B cell responses","volume":"4","author":"Mak","year":"2003","journal-title":"Nat Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-018-0582-8","article-title":"Next generation of immune checkpoint therapy in cancer: new developments and challenges","volume":"11","author":"Marin-Acevedo","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S1074-7613(03)00147-X","article-title":"B7S1, a novel B7 family member that negatively regulates T cell activation","volume":"18","author":"Prasad","year":"2003","journal-title":"Immunity"},{"key":"B23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.trecan.2018.03.010","article-title":"B7-H3 in cancer - beyond immune regulation","volume":"4","author":"Flem-Karlsen","year":"2018","journal-title":"Trends Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S1074-7613(03)00152-3","article-title":"B7-H4, a molecule of the B7 family, negatively regulates T cell immunity","volume":"18","author":"Sica","year":"2003","journal-title":"Immunity"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1158\/1078-0432.CCR-15-2440","article-title":"Molecular pathways: evaluating the potential for B7-H4 as an immunoregulatory target","volume":"23","author":"Macgregor","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1038\/ncomms3043","article-title":"B7-H5 costimulates human T cells via CD28H","volume":"4","author":"Zhu","year":"2013","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1158\/0008-5472.CAN-13-1504","article-title":"VISTA is an immune checkpoint molecule for human T cells","volume":"74","author":"Lines","year":"2014","journal-title":"Cancer Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1158\/0008-5472.CAN-13-3017","article-title":"Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30","volume":"74","author":"Schlecker","year":"2014","journal-title":"Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1158\/1078-0432.CCR-14-1495","article-title":"Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein","volume":"21","author":"Janakiram","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.it.2012.10.001","article-title":"Indoleamine 2,3 dioxygenase and metabolic control of immune responses","volume":"34","author":"Munn","year":"2013","journal-title":"Trends Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.trecan.2017.11.005","article-title":"Inflammatory reprogramming with IDO1 inhibitors: turning immunologically unresponsive \u2018cold' tumors \u2018hot'","volume":"4","author":"Prendergast","year":"2018","journal-title":"Trends Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41568-019-0106-z","article-title":"Immune control by amino acid catabolism during tumorigenesis and therapy","volume":"19","author":"Lemos","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1126\/science.360.6389.588","article-title":"A new cancer immunotherapy suffers a setback","volume":"360","author":"Garber","year":"2018","journal-title":"Science"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/mt.2015.67","article-title":"Mesenchymal stromal cells derived from Crohn's patients deploy indoleamine 2,3-dioxygenase-mediated immune suppression, independent of autophagy","volume":"23","author":"Chinnadurai","year":"2015","journal-title":"Mol Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/j.celrep.2018.02.013","article-title":"Potency analysis of mesenchymal stromal cells using a combinatorial assay matrix approach","volume":"22","author":"Chinnadurai","year":"2018","journal-title":"Cell Rep"},{"key":"B36","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.stemcr.2014.05.003","article-title":"Actin cytoskeletal disruption following cryopreservation alters the biodistribution of human mesenchymal stromal cells in vivo","volume":"3","author":"Chinnadurai","year":"2014","journal-title":"Stem Cell Reports"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e12954","DOI":"10.1097\/MD.0000000000012954","article-title":"Prognostic value of osteopontin in patients with hepatocellular carcinoma: A systematic review and meta-analysis","volume":"97","author":"Sun","year":"2018","journal-title":"Medicine."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.3390\/cancers11091339","article-title":"Glypican 3-targeted therapy in hepatocellular carcinoma","volume":"11","author":"Nishida","year":"2019","journal-title":"Cancers."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.7150\/jca.39972","article-title":"Glypican-3: a new target for diagnosis and treatment of hepatocellular carcinoma","volume":"11","author":"Guo","year":"2020","journal-title":"J Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.3390\/cancers11111689","volume":"11","author":"Giannini","year":"2019","journal-title":"Cancers."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3390\/cancers11081078","article-title":"Immunotherapy in hepatocellular carcinoma: is there a light at the end of the tunnel?","volume":"11","author":"Mahipal","year":"2019","journal-title":"Cancers."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e1207841","DOI":"10.1080\/2162402X.2016.1207841","article-title":"Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer","volume":"5","author":"Xu","year":"2016","journal-title":"Oncoimmunology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1093\/intimm\/dxq049","article-title":"PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1","volume":"22","author":"Ghiotto","year":"2010","journal-title":"Int Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.str.2017.06.011","article-title":"Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1\/PD-L2","volume":"25","author":"Zak","year":"2017","journal-title":"Structure"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Science"},{"key":"B46","doi-asserted-by":"publisher","first-page":"6086","DOI":"10.1038\/s41598-017-06410-w","article-title":"Programmed death one homolog maintains the pool size of regulatory T cells by promoting their differentiation and stability","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"key":"B47","doi-asserted-by":"publisher","first-page":"6682","DOI":"10.1073\/pnas.1420370112","article-title":"Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses","volume":"112","author":"Liu","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B48","doi-asserted-by":"publisher","first-page":"E5900","DOI":"10.1073\/pnas.1706559114","article-title":"Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses","volume":"114","author":"Chew","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cell.2017.05.035","article-title":"Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing","volume":"169","author":"Zheng","year":"2017","journal-title":"Cell."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e86182","DOI":"10.1172\/jci.insight.86182","article-title":"PD-1(+) and Foxp3(+) T cell reduction correlates with survival of HCC patients after sorafenib therapy","volume":"2016","author":"Kalathil","year":"2016","journal-title":"JCI Insight"},{"key":"B51","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3109\/08820139.2012.689405","article-title":"Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance","volume":"41","author":"Johnson","year":"2012","journal-title":"Immunol Invest"},{"key":"B52","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/hep.26694","article-title":"Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma","volume":"59","author":"Han","year":"2014","journal-title":"Hepatology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1002\/hep.27686","article-title":"Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms","volume":"61","author":"Mukhopadhyay","year":"2015","journal-title":"Hepatology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.1158\/0008-5472.CAN-12-0569","article-title":"Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion","volume":"72","author":"Platten","year":"2012","journal-title":"Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/s41379-018-0061-3","article-title":"IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1","volume":"31","author":"Dill","year":"2018","journal-title":"Mod Pathol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/PGP.0000000000000494","article-title":"Targetable immune regulatory molecule expression in high-grade serous ovarian carcinomas in african american women: a study of PD-L1 and IDO in 112 cases from the African American Cancer Epidemiology Study (AACES)","volume":"38","author":"Mills","year":"2018","journal-title":"Int J Gynecol Pathol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"23482","DOI":"10.18632\/oncotarget.25235","article-title":"Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer","volume":"9","author":"Rosenberg","year":"2018","journal-title":"Oncotarget"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1084\/jem.20130066","article-title":"Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4","volume":"210","author":"Holmgaard","year":"2013","journal-title":"J Exp Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s00262-018-2190-4","article-title":"Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma","volume":"67","author":"Brown","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B60","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat","volume":"36","author":"Long","year":"2018","journal-title":"J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/nri3839","article-title":"Perforin and granzymes: function, dysfunction and human pathology","volume":"15","author":"Voskoboinik","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fimmu.2018.00014","article-title":"Recent advances in targeting CD8 T-cell immunity for more effective cancer immunotherapy","volume":"9","author":"Durgeau","year":"2018","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e13301","DOI":"10.1097\/MD.0000000000013301","article-title":"Prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma: a meta-analysis","volume":"97","author":"Ding","year":"2018","journal-title":"Medicine."},{"key":"B64","doi-asserted-by":"publisher","first-page":"S1188","DOI":"10.4103\/0973-1482.204850","article-title":"Expression of programmed death ligand-1 and programmed death 1 in hepatocellular carcinoma and its clinical significance","volume":"14","author":"Long","year":"2018","journal-title":"J Cancer Res Ther"},{"key":"B65","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/1468-4446.12612","article-title":"The social life of DNA: racial reconciliation and institutional morality after the genome - a response","volume":"69","author":"Nelson","year":"2018","journal-title":"Br J Sociol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3389\/fonc.2019.00883","article-title":"Expression of programmed cell death-ligands in hepatocellular carcinoma: correlation with immune microenvironment and survival outcomes","volume":"9","author":"Liao","year":"2019","journal-title":"Front Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1053\/j.gastro.2018.08.030","article-title":"Association between expression level of PD1 by tumor-infiltrating CD8(+) T cells and features of hepatocellular carcinoma","volume":"155","author":"Kim","year":"2018","journal-title":"Gastroenterology."},{"key":"B68","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.3892\/mmr.2019.10080","article-title":"High expression of B7H2 or B7H3 is associated with poor prognosis in hepatocellular carcinoma","volume":"19","author":"Zheng","year":"2019","journal-title":"Mol Med Rep"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1007\/s00262-012-1278-5","article-title":"B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence","volume":"61","author":"Sun","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e22872","DOI":"10.1002\/jcla.22872","article-title":"IDO and intra-tumoral neutrophils were independent prognostic factors for overall survival for hepatocellular carcinoma","volume":"33","author":"Wang","year":"2019","journal-title":"J Clin Lab Anal"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1002\/stem.3028","article-title":"Molecular genetic and immune functional responses distinguish bone marrow mesenchymal stromal cells from hepatic stellate cells","volume":"37","author":"Chinnadurai","year":"2019","journal-title":"Stem Cells"},{"key":"B72","doi-asserted-by":"publisher","first-page":"8067","DOI":"10.1158\/0008-5472.CAN-09-0901","article-title":"Kupffer cell suppression of CD8++ T cells in human hepatocellular carcinoma is mediated by B7-H1\/programmed death-1 interactions","volume":"69","author":"Wu","year":"2009","journal-title":"Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01632\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T04:29:19Z","timestamp":1599107359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01632\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":72,"alternative-id":["10.3389\/fonc.2020.01632"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.01632","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2020,9,3]]},"article-number":"1632"}}